The possibility of neoadjuvant chemotherapy course adjustment for delayed operation of patients with esophageal cancer in special period
10.3760/cma.j.cn112152-20210107-00028
- VernacularTitle:调整食管癌新辅助化疗方案周期以应对特殊时期患者手术延迟的治疗策略探讨
- Author:
Moyan ZHANG
1
;
Yong LI
;
Peng SONG
;
Jianjun QI
;
Yin LI
;
Shugeng GAO
Author Information
1. 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院胸外科 100021
- Keywords:
Esophageal neoplasms;
Neoadjuvant chemotherapy;
Delayed operation;
Adjustment;
Tumor regression
- From:
Chinese Journal of Oncology
2021;43(6):686-690
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of the neoadjuvant chemotherapy course adjustment on the patients with esophageal cancer underwent delayed operation.Methods:The clinical data of patients with esophageal cancer treated in Cancer Hospital, Chinese Academy of Medical Sciences from 2019—2020, who underwent neoadjuvant chemotherapy strategy adjustment (multiple course chemotherapy group) or not (control group), were retrospectively studied. The clinical pathological characteristics and postoperative complication of these two group were compared and analyzed.Results:The cases who underwent the interval between chemotherapy and operation more than 4 weeks in multiple course chemotherapy group and control group were 17 and 6, with significant difference ( P<0.05). The average operative blood loss of these two groups were 88.6 ml and 46.1 ml, the average postoperative hospital stays were 14.7 days and 10.0 days, with significant difference ( P<0.05). The incidence rate of postoperative complication in the multiple course chemotherapy group was 40.9% (9/22), not significantly different from 31.8% (7/22) of control group ( P>0.05). There were no death within postoperative 7 days and 30 days in both groups. Cases with apparent tumor regression [tumor regression grade (TRG) 1 to 3] in multiple course chemotherapy group were 14, with marginal tumor regression (TRG 4 to 5) were 8, while there were 7 and 15 in the control group, respectively, with significant difference ( P<0.05). After multiple neoadjuvant chemotherapy, the imaging examination of patients indicated an almost total tumor degradation and the postoperative pathology showed no residual malignant tumor tissue was observed. Conclusions:Increased neoadjuvant chemotherapy course for patients with locally advanced esophageal cancer can obtain more obvious tumor degradation response. Neoadjuvant chemotherapy adjustment according to the operation schedule is recommended.
